The DF-4 Connector was recently introduced by a joint group of CRM companies, physicians, and regulatory agencies as a way of easing the implant of ICDs by reducing defibrillation connections from three to one and by minimizing the number of set screws. Prior to the development of the DF-4, traditional high-voltage connector systems required up to three connections. Continue reading
Daily Archives: February 2, 2012
Boston Scientific’s Active Implantable Sales for 2011: CRM Down 7%, Neuromodulation Up 10%
Today Boston Scientific Corporation announced financial results for the fourth quarter and full year ended December 31, 2011. Summarizing the AIMD data:
- On a constant-currency basis, Q4 2011 CRM sales were $482M compared to $564M in Q4 2010, or down 15%
- On a constant-currency basis, 2011 CRM sales were $2,087M compared to $2,180M in Q4 2010, or down 7%
- On a constant-currency basis, Q4 2011 Neuromodulation sales were $91M compared to $86M in Q4 2010, or up 6%
- On a constant-currency basis, Q4 2011 CRM sales were $336M compared to $304M in Q4 2010, or up 10%
Click here for the news release.